BridgeBio logo

BridgeBio Funding & Investors

Palo Alto, CA

BridgeBio Pharma, Inc. operates as a pharmaceutical company. The Company discovers and develops drugs for patients with grievous genetic diseases. BridgeBio Pharma offers medicines for different medical areas such as cardiology, neurology, oncology, and dermatology. BridgeBio Pharma serves patients in the State of California.

bridgebio.com

Total Amount Raised: $3,849,199,616

BridgeBio Funding Rounds

  • Post Ipo Equity

    $250,000,000

  • Post Ipo Debt

    $1,250,000,000

    Post Ipo Debt Investors

    Blue Owl
    CPPIB Credit Investments
  • Post Ipo Equity

    $250,000,000

    Post Ipo Equity Investors

    Qatar Investment Authority
  • Post Ipo Equity

    $150,000,000

  • Post Ipo Debt

    $750,000,000

  • Post Ipo Debt

    $250,000,000

  • Post Ipo Debt

    $475,000,000

  • Series D

    $299,200,000

    Series D Investors

    KKR
    Viking Global Investors
    Hercules Capital
    Aisling Capital
    Cormorant Capital
    AIG Investments
    Sequoia Capital
    Perceptive Advisors
  • IPO

    Unknown

  • Series C

    $135,000,000

    Series C Investors

    KKR
    Viking Global Investors
    Perceptive Advisors
    AIG Investments
    Aisling Capital
    Cormorant Capital
    Janus Fund
  • Series B

    $33,100,000

    Series B Investors

    KKR
  • Series B

    $6,900,000

    Series B Investors

    KKR
Funding info provided by Diffbot.